Founder, Ceo
Current-Developing the CardiaZn, a bioresorbable metallic stent to treat congenital heart defects in neonates.-Selected by the FDA in 2023 as a Break Through Technology and the first device accepted into the FDA's new Total Product Life Cycle Advisory Program (TAP).-Principal Investigator on a $3.4 million SBIR Fast Track grant from the National Institutes of.